
About


Re-Launch of UK’s Innovative Licensing and Access Pathway (“ILAP”)
MHRA Consultation on Individualised mRNA Cancer Immunotherapies – Unique opportunity for a streamlined risk based regulatory framework?

MHRA Consultation on Individualised mRNA Cancer Immunotherapies – Unique opportunity for a streamlined risk based regulatory framework?

European Commission Consults on Update to Pharmacovigilance Rules

Are you Windsor Framework ready? A focus on pharmaceutical supply chains and promotional material
MHRA Consults on New UK Pre-Market Medical Device Measures
